 GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 05, 2021 GLOBE NEWSWIRE -- Applied Genetic Technologies Corporation Nasdaq: AGTC, a biotechnology company conducting human clinical trials of adeno-associated virus AAV-based gene therapies for the treatment of rare retinal diseases, today announced that it plans to release 12-month data for Groups 5 and 6 evaluating durability of effect and continued safety at higher doses and 24-month data evaluating durability from a subset of Group 4 patients for its Phase 12 clinical trial in patients with X-linked Retinitis Pigmentosa XLRP on Thursday, May 6, 2021. AGTC management will host a conference call and webcast with accompanying slides to review the data and provide a general update on the XLRP trial beginning at 8:00 AM Eastern Time on the same date. 